# Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Source: https://onco.cc/trials/nct05053971/  
OnCo record `nct05053971` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors is a phase 1/2, interventional study registered as NCT05053971 by National Cancer Institute (NCI), with a registry enrolment figure of 49 participants, started 2022-11-16 and due to reach its primary completion in 2027-07-01. Interventions recorded: BET Bromodomain Inhibitor ZEN-3694; Computed Tomography; Core Biopsy; Entinostat. Conditions listed: Advanced Malignant Solid Neoplasm; Locally Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma. Primary outcome: Maximum tolerated dose (MTD) (Phase Ib); Recommended phase 2 dose (RP2D) (Phase Ib); Objective response rate (ORR) (Phase II). Pancreatic eligibility wording from the registry: "* For patients in Phase 2: Patients must have locally advanced, unresectable OR metastatic pancreatic cancer refractory to standard therapy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05053971
- Phase: 1/2
- Setting: Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT05053971: https://clinicaltrials.gov/study/NCT05053971

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05053971.json